# Dr Ilian Iliev

> Dr Ilian Iliev is a venture - series unknown investor at EMV Capital backing Medical and Software. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EMV Capital](https://shizune.co/investors/profile/ecomachines-ventures)
- Location: London, United Kingdom
- Total investments: 15
- Last investment: Dec 2025
- Lead investor: 87%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/ilianiliev
- X (Twitter): http://twitter.com/ILIAN_P_ILIEV
- Website: https://x.com/ILIAN_P_ILIEV

Dr Ilian Iliev is a venture - series unknown investor at EMV Capital in London focused on Medical and Software. Dr. Ilian Iliev, Chief Executive Officer of NetScientific PLC, is also Managing Director of EMV Capital (EMVC), a corporate finance and VC investment firm acquired by NetScientific in August 2020. EMVC is a London-based investor in the industrial sustainability, industrials and healthcare sectors. EMVC’s investments in Europe, Israel and the UScover a range of technologies including robotics and AI, machine learning, materials science, IoT, advanced engineering, power electronics and medical devices. Ilian spun-out EMV Capital out of EcoMachines Ventures, which he co-founded in 2013. Prior to that he co-founded and was CEO of CambridgeIP Ltd (2006-2012), which he built into a leading market and technology business intelligence provider in the UK. He is a Board member at a number of Net Scientific and EMVC portfolio companies, including PDS Biotechnology Inc., Glycotest Inc., Sofant Technologies, Pointgrab, Q-Bot, Wanda Health, and also serves as Executive Chairman at Vortex Biosciences Inc.Ilian holds a PhD from Cambridge University ’s Judge Business School, focused on Venture Capital business models in emerging economies, Mcom in Economics, and BA in Politics, Economics and International Relations from the University of Witwatersrand, South Afirca. He has published widely on entrepreneurship, venture capital, and market trends in energy and healthcare, and has won awards for academic excellence.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 13% |
| Software | 2 | 13% |
| Health Care | 2 | 13% |
| Machine Learning | 2 | 13% |
| Artificial Intelligence | 2 | 13% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 4 | 27% |
| Funding Round | 3 | 20% |
| Seed | 2 | 13% |
| Series A | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 3 | 20% |
| United States | 2 | 13% |
| Israel | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sofant Technologies | Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems. | $8.4M | Venture - Series Unknown | Dec 23, 2025 |  |
| Sofant Technologies | Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems. | $4.3M | Venture - Series Unknown | Jun 05, 2024 |  |
| Q-Bot | Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Boardand The Department for Energy and Climate Change. | $4.4M | Venture - Series Unknown | Sep 13, 2023 |  |
| DName-iT | DName-iT is a genetic analysis tool that offers DNA-based barcode labeling technology and a software platform that can ensure reliable, cost-effective NGS specimen identification. | $634K | Seed | Jun 30, 2023 |  |
| Sofant Technologies | Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems. | $5M | Venture - Series Unknown | Nov 29, 2022 |  |
| EpiBone | EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superiorbone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. |  | Venture - Series Unknown | Nov 26, 2022 |  |
| Q-Bot | Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Boardand The Department for Energy and Climate Change. | $2.1M |  | Jun 15, 2022 |  |
| Q-Bot | Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Boardand The Department for Energy and Climate Change. | $1.9M | Series A | Jun 14, 2022 |  |
| Sofant Technologies | Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems. | $1.2M | Venture - Series Unknown | Oct 26, 2021 |  |
| PointGrab | PointGrab Ltd. develops machine learning technology installed in optical IoT sensors for commercial Real Estate. The sensors enables Companies to better manage their real estate, increase efficiency and cut Real Estate costs, while keeping Employees' privacy and welfare.PointGrab is considered marker leader in providing occupancy and smartbuilding features in commercial Real Estate. | $4.8M | Venture - Series Unknown | May 20, 2021 |  |

10 of 15 investments shown.

## Co-investors
- [Kelvin Capital](https://shizune.co/investors/profile/kelvin-capital) — VC Fund, 10 deals together
- [NetScientific PLC](https://shizune.co/investors/profile/netscientific) — VC Fund, 4 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 4 deals together
- [Wealth Club](https://shizune.co/investors/profile/wealth-club) — VC Fund, 3 deals together
- [Old College Capital](https://shizune.co/investors/profile/old-college-capital) — VC Fund, 2 deals together
- [Scottish Investment Bank](https://shizune.co/investors/profile/scottish-investment-bank) — VC Fund, 2 deals together

## About EMV Capital

VC Fund · London, United Kingdom

EMV Capital is an award-winning VC investor specialising in early stage high-growth deep tech companies in the life science, sustainability and industrials sectors in the UK and internationally. EMV Capital develops unique investment strategies for each portfolio company, drawing on its EIS fund and extensive network of private investors, familyoffices, institutions, and corporate VCs. Delivery and successful execution of these investment strategies enables innovative portfolio companies to raise funding to drive transformational growth.EMV Capital is a wholly owned subsidiary of NetScientific plc (AIM:NSCI), a life sciences and technology commercialisation and investment group. EMV Capital has a multi-disciplinary team of specialist investors, portfolio managers, capital raisers, legal, finance, marketing and support staff. The company is focused on primary and secondary investments, through debt and/or equity.

5 contacts available at EMV Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dr Ilian Iliev | Managing Director | https://shizune.co/investors/profile/ilian-iliev |
| Oliver Saban | Head of Business Development | https://shizune.co/investors/profile/oliver-saban |
| Charles Laughton | Associate Director, Corporate Finance | https://shizune.co/investors/profile/charles-laughton-d5d5 |
| Edward Hooper | Director | https://shizune.co/investors/profile/edward-hooper-83b1 |
| Gianluca Forino | Private Client Manager | https://shizune.co/investors/profile/gianluca-forino |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Dr Ilian Iliev invest in?

Dr Ilian Iliev invests primarily in Medical, Software and Health Care startups, most often at Venture - Series Unknown and Funding Round stage. Most of the 15 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dr Ilian Iliev last invest?

The most recent investment recorded for Dr Ilian Iliev closed in Dec 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co